Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MCRB Seres Therapeutics	$16.86 +5.6%	$11.74	$6.53 ▼ $26.40	$139.81M	2.9	126,564 shs	208,903 shs
PRTC PureTech Health	$17.50 +3.0%	$18.22	$13.30 ▼ $25.00	$410.00M	1.12	2,626 shs	5,409 shs
SIGA Siga Technologies	$8.58 -2.3%	$6.91	$4.95 ▼ $11.91	$628.70M	0.94	581,263 shs	507,609 shs
TERN Terns Pharmaceuticals	$6.77 +4.3%	$4.94	$1.87 ▼ $11.40	$567.95M	-0.05	1.11 million shs	1.21 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MCRB Seres Therapeutics	+5.57%	+10.27%	+14.93%	+126.01%	-6.65%
PRTC PureTech Health	-1.38%	-1.69%	-0.88%	+2.22%	-24.70%
SIGA Siga Technologies	-2.28%	+0.35%	+28.06%	+43.24%	-28.32%
TERN Terns Pharmaceuticals	+4.31%	+20.04%	+34.06%	+135.07%	+4.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MCRB Seres Therapeutics	3.2446 of 5 stars	2.9	1.0	4.6	2.7	0.8	0.0
PRTC PureTech Health	2.7749 of 5 stars	3.8	5.0	0.0	2.7	0.0	0.0
SIGA Siga Technologies	2.0791 of 5 stars	0.0	2.0	0.0	2.5	0.8	3.1
TERN Terns Pharmaceuticals	4.0271 of 5 stars	3.3	1.0	4.1	3.4	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MCRB Seres Therapeutics	1.75	Reduce	$73.67	336.93% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	157.14% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A
TERN Terns Pharmaceuticals	2.60	Moderate Buy	$15.63	130.80% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MCRB Seres Therapeutics	$126.32M	1.17	N/A	N/A	$3.76 per share	4.48
PRTC PureTech Health	$4.32M	97.87	$2.45 per share	7.13	$17.04 per share	1.03
SIGA Siga Technologies	$138.72M	4.43	$0.82 per share	10.49	$2.92 per share	2.94
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	$3.49 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$1.13	7.59	6.86	N/A	45.73%	40.52%	35.62%	N/A
TERN Terns Pharmaceuticals	-$88.85M	-$1.04	N/A	N/A	N/A	N/A	-27.35%	-26.18%	N/A

Latest MCRB, TERN, SIGA, and PRTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million
8/5/2025	Q2 2025	TERN Terns Pharmaceuticals	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A
TERN Terns Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MCRB Seres Therapeutics	N/A	1.57	1.57
PRTC PureTech Health	N/A	9.33	9.33
SIGA Siga Technologies	N/A	10.09	8.52
TERN Terns Pharmaceuticals	N/A	24.70	24.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MCRB Seres Therapeutics	59.34%
PRTC PureTech Health	0.04%
SIGA Siga Technologies	55.40%
TERN Terns Pharmaceuticals	98.26%

Insider Ownership

Company	Insider Ownership
MCRB Seres Therapeutics	4.70%
PRTC PureTech Health	5.30%
SIGA Siga Technologies	1.95%
TERN Terns Pharmaceuticals	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
PRTC PureTech Health	100	24.13 million	22.85 million	Not Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable
TERN Terns Pharmaceuticals	40	87.51 million	86.20 million	Not Optionable

MCRB, TERN, SIGA, and PRTC Headlines

Recent News About These Companies

5 Oral Obesity Drugs Challenging Lilly’s Orforglipron

August 12 at 2:18 AM | biospace.comB

William Blair Has Positive Outlook of TERN FY2025 Earnings

August 9, 2025 | marketbeat.com

Terns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

August 6, 2025 | marketbeat.com

Terns Seeks Partners for Metabolic Assets Amid Oversaturated Obesity Market

August 6, 2025 | biospace.comB

Terns to stop funding metabolic disease trials beyond 2025, seeks partners for assets

August 6, 2025 | fiercebiotech.comF

Terns (TERN) Q2 Net Loss Narrows 16%

August 6, 2025 | fool.com

Brokerages Set Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Target Price at $15.63

August 6, 2025 | americanbankingnews.com

Terns Pharmaceuticals Reports Q2 2025 Financial Results

August 6, 2025 | tipranks.com

Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 5, 2025 | globenewswire.com

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

August 4, 2025 | globenewswire.com

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 3, 2025 | marketbeat.com

Terns Pharmaceuticals (TERN) to Release Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting

July 14, 2025 | biospace.comB

Terns Pharmaceuticals CEO & Director Acquires 98% More Stock

July 4, 2025 | finance.yahoo.com

Terns pharmaceuticals CEO Burroughs buys $90k in shares

June 27, 2025 | investing.com

Rivus' weight loss drug scores MASH phase 2 win, showcases muscle-sparing potential

June 26, 2025 | fiercebiotech.comF

Terns Pharmaceuticals Presents Promising Phase 1 Data for TERN-601 at ADA 2025 and Completes Enrollment for Phase 2 FALCON Trial - Nasdaq

June 24, 2025 | nasdaq.com

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American ... - Morningstar

June 24, 2025 | morningstar.comM

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

June 23, 2025 | medpagetoday.comM

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

June 23, 2025 | globenewswire.com

Population-Level Weight Loss Seen With Primary Care Protocol

June 21, 2025 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MCRB, TERN, SIGA, and PRTC Company Descriptions

Seres Therapeutics NASDAQ:MCRB

$16.86 +0.89 (+5.57%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$17.09 +0.23 (+1.36%)

As of 08/14/2025 07:57 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

PureTech Health NASDAQ:PRTC

$17.50 +0.51 (+3.00%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$17.50 0.00 (0.00%)

As of 08/14/2025 04:36 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Siga Technologies NASDAQ:SIGA

$8.58 -0.20 (-2.28%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$8.58 0.00 (0.00%)

As of 08/14/2025 05:39 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Terns Pharmaceuticals NASDAQ:TERN

$6.77 +0.28 (+4.31%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$6.76 -0.01 (-0.22%)

As of 08/14/2025 07:46 PM Eastern

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time